Bacteriophage клебсиелл pneumonia cleared
Producer: Federal state unitary enterprise NPO Mikrogen Russia
Code of automatic telephone exchange: V03A
Pharm group: a href="javascript:if(confirm(%27medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57 \n\nThis file was not retrieved by Teleport Pro, because it is linked too far away from its Starting Address. If you increase the in-domain depth setting for the Starting Address, this file will be queued for retrieval. \n\nDo you want to open it from the server?%27))window.location=%27medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57%27" tppabs="medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57">Other different drugs
Release form: Liquid dosage forms. Solution for intake.
General characteristics. Structure:
Active ingredient: 20 ml of bacteriophages клебсиелл pneumonia (the sterile cleared filtrate of a fagolizat of Klebsiella pneumonia).
Excipients: 8 hydroxyquinolines of sulfate monohydrate.
Pharmacological properties:
Pharmacodynamics. Drug causes a specific lysis of bacteria of Klebsiella pneumoniae.
Indications to use:
Treatment and prevention of the diseases caused by Klebsiella pneumonia bacteria as a part of complex therapy:
— digestive tract diseases (gastroenterocolitis, cholecystitis, pancreatitis, intestinal dysbiosis);
— inflammatory diseases of newborns and children of early age (gastroenterocolitis, intestinal dysbiosis, omphalitis, pempigus, pyoderma, septicaemia and septicopyemia of various localization);
— surgical infections (suppurations of wounds, purulent damages of skin, burns, peritonitis, pleurisy, mastitis, osteomyelitis, abscess);
— urogenital infections (cystitis, pyelonephritis, urethritis, endometritis, vulvitis, bartholinitis, colpitis, salpingo-oophoritis);
— pyoinflammatory diseases of an ear, throat, nose, bosoms of a nose, oral cavity, throat, throat, bronchial tubes, lungs and pleura (otitis, quinsy, pharyngitis, laryngitis, stomatitis, periodontal disease, antritis, frontal sinusitis, bronchitis, pneumonia, pleurisy);
— posttraumatic conjunctivitis, keratoconjunctivitis, purulent helcoma and iridocyclitis;
— prevention of the intrahospital infections caused by klebsiyella.
Important condition of an effective phagotherapy is preliminary definition of a phagosensitivity of the activator.
Route of administration and doses:
Drug is used for intake (through a mouth), in the form of enemas, applications, irrigations, by introductions to cavities of wounds, vaginas, a uterus, a nose, nose bosoms, and also in the trained cavities: abscesses, belly, pleural, bladder, renal pelvis.
Inside drug is accepted on an empty stomach in 0,5-1 hour prior to meal.
The recommended drug doses:
img src="http://medicalmeds.eu/img/data:image/png;base64,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" alt="" />
Treatment of pyoinflammatory diseases with the localized defeats has to be carried out at the same time as locally, and administration of drug inside.
In case of processing of a cavity of a suppurative focus chemical antiseptic agents before use of a bacteriophage it has to be washed out sterile 0,9% by chloride sodium solution.
At treatment of quinsies, pharyngitises, laryngitis drug 3 times a day on 10-20 ml use for rinsings of an oral cavity and throat, a course of treatment of 7-10 days.
At treatment of bronchitis, pneumonia drug is accepted inside by 3 times a day on 10-20 ml, and also apply in the form of inhalations (without heating and use of ultrasound), a course of treatment of 15-20 days.
At treatment of otitises drug is used for washing and introduction to a tympanic cavity on 2-5 ml by 1-3 times a day. Course of treatment of 7-15 days.
At treatment of inflammations of bosoms of a nose drug is used for washing of a nasal cavity, a nasopharynx and bosoms of a nose in a dose of 5-10 ml and by introductions to bosoms of 2-3 ml. The procedure is repeated daily once within 7-10 days. Besides, the drug is administered in a nasal cavity in the form of the turundas moistened with a bacteriophage in turn in each nasal course and left within 0,5-1 hours. The procedure 3 times a day repeat, a course of treatment of 7-15 days.
At treatment of stomatitises and chronic generalized parodontit drug 3-4 times a day in a dose use in the form of rinsings of an oral cavity 10-20 ml, and also introduction to parodontalny pockets of the turundas impregnated with a bacteriophage клебсиелл for 5-10 min., a course of treatment of 7-10 days.
At conjunctivitis and keratoconjunctivites, drug is used on 2-3 drops of 4-5 times a day, a course of treatment of 5-7 days; at a purulent helcoma - on 4-5 drops a day within 7-10 days, at purulent iridocyclites - on 6-8 drops each 3 hours in combination with intake in therapeutic dosages within 7-10 days.
At abscesses after opening and removal of purulent contents the drug is administered in quantity smaller, than the volume of remote pus daily once, a course of treatment of 7-10 days.
At peritonitises and pleurisy the drug is administered in the trained cavities - belly and pleural through drainage tubes daily once 20-70 ml, a course of treatment of 10-15 days.
At osteomyelites the drug is administered in a wound cavity through turundas, drainages in number of 10-30 ml daily once, a course of treatment of 15-20 days.
At treatment of suppurations of wounds drug is used in the form of irrigation, applications, bandages, by introductions to a drainage in a dose of 5-50 ml depending on the center to the porazheniyena less once a day, a course of treatment of 10-15 days.
At treatment of pyoinflammatory gynecologic diseases (suppurations of wounds, endometritises, vulvit, bartholinites, colpitises, salpingo-oophorites) drug is used for irrigations, applications, enter into cavities of wounds, vaginas, a uterus 5-20 ml within 7-10 days once a day.
At cystitis, pyelonephritises, uretrita drug is accepted inside in a therapeutic dose by 3 times a day in 1 hour prior to food within 10-20 days. If the cavity of a bladder or a renal pelvis are trained, the drug is administered through tsistosty or nefrosty 1-3 once a day on 20-50 ml in a bladder and 5-7 ml in a renal pelvis, a course of treatment of 7-15 days.
At gastroenterocolites, pancreatitis, cholecystitises, and also intestinal dysbioses the bacteriophage is accepted inside in age dosages by 3 times a day in 1 hour prior to food within 7-15 days (according to clinical indications). At pernicious vomiting drug is used in the form of high enemas by 2-3 times a day on 20-40 ml. At an intestinal dysbiosis drug can be used with drugs normoflor.
For prevention of intrahospital surgical infections drug use for processing of postoperative and svezheinfitsirovanny wounds in a dose 5 - 50 ml depending on the defeat center daily once within 5-7 days.
Use of drug for children till 1 year (including premature children). At a gastroenterocolitis, pneumonia and sepsis of newborns drug is used through a mouth by 2-3 times a day on 3-5 ml in 30 minutes prior to feeding. In cases of pernicious vomiting drug is used in the form of high enemas (through a colonic tube or a catheter) daily once in a dose of 5-10 ml. The combination rectal (in the form of high enemas) and пероралыюго drug uses is possible. A course of treatment of 7-15 days (according to clinical indications). At the recurrent course of a disease perhaps repeated carrying out courses of treatment.
For the purpose of prevention of developing of an intrahospital infection at newborn children the bacteriophage is applied according to epidemic indications inside on 3-5 ml by 3 times a day in 30 minutes prior to feeding during all term of stay in a hospital.
At treatment of omphalites, pyodermas, contaminated wounds apply a bacteriophage in the form of applications on 5-10 ml 2-3 times a day (the gauze napkin is moistened with a bacteriophage and impose on an umbilical wound or an affected area of skin) within 7-15 days.
Use of drug does not exclude use of other antibacterial and antiinflammatory drugs.
Features of use:
Use at pregnancy and feeding by a breast. Use of this drug at pregnancy and during feeding by a breast perhaps in the presence of the infections caused by fagochuvstvitelny strains клебсиелл (according to the recommendation of the doctor).
Use for children. Use for children according to indications is possible.
Special instructions. Precautionary measures at use. At opacification not to use drug!
Owing to the content in drug of a medium in which bacteria from the environment can develop, causing drug opacification, it is necessary to follow the following rules when opening a bottle:
— to carefully wash hands;
— to process a cap alcohol-containing solution;
— to remove a cap, without opening a stopper;
— not to put a stopper an internal surface on a table or other objects;
— not to leave a bottle open;
— to store the opened bottle only in the refrigerator.
When using small doses (2-8 drops) drug needs to be selected the sterile syringe of 0,5-1 ml.
Drug from the opened bottle at observance of storage conditions, above-mentioned rules and lack of opacification can be used during all period of validity.
Influence on ability to driving of motor transport and to control of mechanisms. No.
Side effects:
Are not established.
Interaction with other medicines:
Use of drug is possible in combination with other medicines, including with antibiotics.
Contraindications:
— hypersensitivity to drug components.
Overdose:
It is not established.
Storage conditions:
Drug is stored according to the joint venture 3.3.2.1248-03 in dry protected from light and the place, unavailable to children, at a temperature from 2 to 8 °C. A period of validity - 2 years.
Issue conditions:
Without recipe
Packaging:
20 ml - bottles glass (4) - packs cardboard.
20 ml - bottles glass (10) - packs cardboard.
20 ml - bottles glass (4) - planimetric strip packagings (1) - packs cardboard.